Mary Dolan to Testicular Neoplasms
This is a "connection" page, showing publications Mary Dolan has written about Testicular Neoplasms.
Connection Strength
2.779
-
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816.
Score: 0.665
-
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
Score: 0.552
-
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5757-5768.
Score: 0.478
-
Impact of pain and adverse health outcomes on long-term US testicular cancer survivors. J Natl Cancer Inst. 2024 03 07; 116(3):455-467.
Score: 0.190
-
Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv. 2023 02; 17(1):27-39.
Score: 0.176
-
Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy. J Clin Oncol. 2023 04 20; 41(12):2211-2226.
Score: 0.176
-
Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. Ear Hear. 2022 May/Jun; 43(3):794-807.
Score: 0.168
-
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. J Natl Compr Canc Netw. 2019 05 01; 17(5):459-468.
Score: 0.136
-
Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res. 2017 07 01; 23(13):3325-3333.
Score: 0.116
-
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010 Aug 04; 102(15):1114-30.
Score: 0.074
-
Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy. JAMA Oncol. 2024 Jul 01; 10(7):912-922.
Score: 0.049